COR vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Cencora (COR) trades at a premium valuation with strong 5-year price performance (+271.1%) and solid earnings growth (YoY EPS +15.0%), supported by consistent quarterly beats (22 of 25 quarters) and improving margins. However, its profitability metrics remain weak relative to peers—particularly gross margin (3.51%) and operating margin (1.14%)—while elevated leverage (Debt/Equity 4.38) and deteriorating liquidity (Current Ratio 0.90) raise structural concerns. The stock is priced for perfection with a P/E of 45.47, well above the sector average of 36.87, despite lower-than-peer revenue growth (5.9% vs 10.5%). Notably, recent insider selling totaling $18.51M over the past six months contrasts with a bullish analyst consensus, creating a mixed signal that tempers enthusiasm.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
COR vs LLY: Head-to-Head Comparison
This page compares Cencora, Inc. (COR) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.